摘要
目的评价培美曲塞治疗晚期化疗后进展的非小细胞肺癌的疗效和毒副反应。方法46例经病理确诊既往化疗失败的晚期非小细胞肺癌患者,培美曲塞500mg/m2静脉滴注,第1天,每21d为1个周期,并口服地塞米松、叶酸和肌内注射维生素B12以减轻毒副反应。根据RECIST标准对客观缓解率进行评价,毒副反应评价按美国NCI制定的毒性评价标准。结果46例可评价,总RR为10.6%。疾病控制率为45.7%,中位无进展生存期为3个月,中位生存期为7个月。毒副反应主要是中性粒细胞下降。结论培美曲塞治疗既往化疗失败的晚期非小细胞肺癌,具有较好的疗效和安全性。
Objective To observe the safety and efficacy of pemetrexed in patients with locally advanced or metastatic non-small cell lung cancer（NSCLC） after previous chemotherapy. Methods A total of 46 patients with pathologically-confirmed NSCLC, received pemetrexed 500 mg/m^2 over Day 1 ivgtt of a 21-day cycle. Patients also received oral dexamethasone, oral folio acid and i.m. vitamin BI： supplementation to reduce toxicity. Tumor response was measured using the RECIST criteria. NCI CTC 2. 0 was used to rate toxicity. Results 46 patients were evaluable for response and toxicity. The objective response rate was 10. 9%. The disease control rate was 45.7%. The median progression-free survival time was 3 months. The median overall survival time was 7 months. The most common toxicities were neutropenia. Conclusion Pemetrexed is effective and safe in treating patients with locally advanced or metastatic NSCLC after failure of previous chemotherapy.
出处
《中国实用医药》
2009年第12期25-26,共2页
China Practical Medicine
关键词
培美曲塞
非小细胞肺癌
化学疗法
Pemetrexed
Non-small-cell lung cancer
Chemotherapy
